Join us in kicking off our 2025-2026 academic year's SPARK Studio sessions, with Jack Armstrong the Business Development Manager for ERBC in the UK and Ireland. To join this online session, please register here.
Are you developing a novel therapeutic and wondering what preclinical studies you need, when to start them, and which guidelines to follow? Join us for an in-depth webinar that unpacks the fundamentals of preclinical development, helping you navigate the complexities of regulatory requirements and timelines with confidence.
This session will cover:
When preclinical studies are required in the drug development lifecycle
Types of studies needed, including pharmacology, toxicology, safety pharmacology, and ADME#
Typical study durations and planning considerations
Key regulatory guidelines and authorities (EMA, MHRA, FDA, ICH) that inform study design and approval
How to ensure compliance with GLP and international standards
Common pitfalls and how to avoid delays during preclinical planning and execution
We’ll also be showcasing how ERBC, a leading preclinical CRO, supports biotech and pharma companies through this critical phase. ERBC is a full-service preclinical Contract Research Organisation (CRO) with over 50 years of experience. ERBC guides innovative life science companies through the complexities of preclinical development from early discovery to IND-enabling regulatory studies. By bridging emerging biotech and large pharma with highly specialized preclinical services, ERBC helps de-risk drug development programs and accelerate time-to-clinic. With a broad scientific offering and expert teams across diverse therapeutic areas, ERBC is committed to helping the right drugs reach the patients who need them most.
This webinar is sponsored through Aston University’s active involvement with the West Midlands Health Tech Innovation Accelerator (WMTHIA). The WMHTIA is funded by the Department for Science, Innovation and Technology, in partnership with the West Midlands Combined Authority and Innovate UK.